CHICAGO--(BUSINESS WIRE)--Jun. 1, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today will present interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. SGN-CD19A is an ADC targeting CD19, a protein expressed on B-cell malignancies. “We continue to make strong progress advancing our proprietary pipeline programs, with SGN-CD19A representing one of five ADCs in clinical development. SGN-CD19A targets a promising cance...

-AbbVie Presents First Phase 1 Data Evaluating Novel ADC Candidate ABT-414 in Glioblastoma- -Genentech Presents Preliminary Phase 2 Results Evaluating Two ADC Candidates, Polatuzumab Vedotin and Pinatuzumab Vedotin, in Relapsed/Refractory Non-Hodgkin Lymphoma- CHICAGO--(BUSINESS WIRE)--May 31, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from several collaborator antibody-drug conjugate (ADC) programs presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. AbbVie presented preliminary data from an ongoing phas...

BOTHELL, Wash.--(BUSINESS WIRE)--May 29, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Jefferies Global Healthcare Conference on Tuesday, June 3, 2014, at 2:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in deve...

BOTHELL, Wash.--(BUSINESS WIRE)--May 14, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. With over 16 years of experience and knowledge in ADC innovation, Seattle Genetics is the leader in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Of the more than 30 ADC candidates in ...

BOTHELL, Wash.--(BUSINESS WIRE)--May 7, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section.   Bank of America Merrill Lynch Annual Health Care Conference Wednesday, May 14, 10:00 a.m. Pacific Time, Las Vegas   ...

-Total First Quarter Revenues of $68.3 Million, Including $38.7 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--May 1, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended March 31, 2014. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments, progress with its antibody-drug conjugate (ADC) pipeline, collaborator updates and upcoming activities. “Our financial and business results to dat...

BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 16, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, May 1, 2014 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Telephone 888-549-7880 (domestic) or 480-629-9644 (international); conference ID 4679217...

$6 Million in Milestone Payments Triggered by Achieving First Commercial Sales of ADCETRIS in Australia, South Korea and Mexico for Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 8, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive milestone payments from Takeda Pharmaceutical Company Limited (Takeda) totaling $6 million as a result of achieving the first commercial sale of ADCETRIS (brentuximab vedotin) in three key countries in Takeda’s territories outside of the European Union and Japan, consisting of Aus...

-Seattle Genetics’ ADC Technology Featured in More Than 15 Presentations- -Multiple Preclinical Data Presentations Highlight Novel ADC Technology Advances and Support Program Development Plans- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 7, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted research related to its antibody-drug conjugate (ADC) programs and technology in more than 15 presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held April 5 to 9, 2014 in San Diego, CA. The presentations describe promising advances that further enhance its ADC...

-Interim Data Demonstrate 92 Percent Objective Response Rate in Ongoing Phase 1/2 Clinical Trial Evaluating ADCETRIS in Combination with Bendamustine for the Treatment of Salvage Hodgkin Lymphoma- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 27, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data at the 2014 Bone Marrow Transplant (BMT) Tandem Meetings being held February 26 to March 2, 2014, in Dallas, Texas. Presentations included the first report from an ongoing phase 1/2 clinical trial evaluating the combination of ADCETRIS and bendamustine in the treatment of salvage Hodgkin ...